流感创新药亮“中国方案”！创新药替代进口加速？

Core Viewpoint - The article highlights the rapid approval and commercialization of domestic influenza antiviral drugs in China, suggesting that 2025 may be regarded as the "Year of Domestic Influenza Innovation Drugs" due to the continuous improvement of China's pharmaceutical innovation capabilities [1]. Group 1: Commercialization of Domestic Influenza Drugs - From March to July 2025, three domestic antiviral drugs (Mashu Lashawei Tablets, Angladwei Tablets, and Mase Luoshawei Tablets) were approved for market entry, with two more (Madu Nuo Shawei and Mapaqi Shawei) completing clinical trials and applying for approval [3][4]. - Sales of these domestic innovative drugs are steadily increasing, indicating recognition of their efficacy and safety [3]. Group 2: Market Potential and Competition - The global seasonal influenza cases are estimated at around 1 billion annually, with 3 to 5 million severe cases, indicating a vast market for antiviral drugs [4]. - The Chinese antiviral drug market is projected to grow at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2028, potentially reaching 26.9 billion yuan by 2028 [4]. - Despite strong demand, the domestic market has been dominated by imported drugs, with Oseltamivir holding over 80% market share in 2023 [4]. Group 3: Factors Driving Innovation - The rise of domestic influenza innovative drugs is attributed to a combination of policy support, technological advancements, and capital investment, marking a significant transformation in the industry [6]. - The National Medical Products Administration has implemented measures to accelerate drug approval processes, resulting in a rapid increase in the number of approved innovative drugs, with 48 approved in 2024 and 43 in the first half of 2025, a 59% year-on-year increase [7]. - The Chinese biopharmaceutical industry is developing rapidly, with the total value of biopharmaceutical business development (BD) transactions exceeding 100 billion USD in 2025, expected to reach 265.9 billion USD by 2030, with a CAGR of 31.3% from 2024 to 2030 [7]. Group 4: Market Sentiment and Future Outlook - Recent catalysts in the innovative drug sector, including the results of national health insurance negotiations and international conferences, are expected to improve market sentiment [8]. - The article suggests that despite recent adjustments in the sector, the trend of "innovation + internationalization" remains strong, with potential for recovery in the innovative drug sector [8].